Stockwinners Market Radar for April 26, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:14 EDT Cathie Wood's ARK Investment sold 223K shares of Shopify today

20:12 EDT Cathie Wood's ARK Investment bought 76K shares of Intellia Therapeutics today

20:10 EDT Cathie Wood's ARK Investment bought 182K shares of Invitae today

19:50 EDT Evo Acquisition terminates business combination pact with 20Cube Logistics - Evo Acquisition "announced that Evo, 20Cube Logistics Solutions Pte. Ltd., Hollis Merger Sub, Inc., 20Cube Logistics Pte. Ltd. and certain holders of outstanding shares of 20Cube Logistics Pte. Ltd. have mutually agreed to terminate their previously announced business combination agreement, effective as of April 25, 2023. The business combination agreement was signed on October 18, 2022. The parties have signed an agreement terminating the business combination agreement on mutually acceptable terms, which also makes void the ancillary documents."

18:58 EDT Westport receives Nasdaq notification regarding minimum bid price - Westport Fuel Systems announced that on April 26, 2023, it received a written notice from The Nasdaq Stock Market LLC notifying that it is currently not in compliance with the minimum bid price requirement set forth under Nasdaq Listing Rule 5450(a)(1). The company also announced that the Board has approved a consolidation of the company's issued and outstanding common shares at a consolidation ratio of 10-for-1.

18:20 EDT Tradeweb Markets in advanced discussions to acquire Yieldbroker - Tradeweb Markets released the following statement: "Tradeweb is in advanced discussions to acquire Yieldbroker, a leading Australian government bond and interest rate derivatives trading platform covering the institutional, wholesale, and primary markets. Tradeweb anticipates that the acquisition would be an all-cash transaction with a purchase price of AUD 125 million. We believe this transaction would leverage both firms' innovative trading solutions and deep industry experience to create more liquid, transparent and efficient fixed income markets. This acquisition would provide Yieldbroker's domestic client network, including superannuation funds, with access to Tradeweb's global multi-asset platform, deep liquidity and advanced technology. Conversely, Tradeweb customers worldwide would benefit from increased liquidity, pre-trade transparency, and coverage of the Australian and New Zealand debt capital markets. Australia is home to the 5th largest pension fund market globallyi, and we believe that this acquisition would help grow Tradeweb's Asia Pacific footprint and provide meaningful opportunities for domestic and global clients. Tradeweb can offer no assurance that a definitive agreement will be entered into, or if entered into that a transaction will be consummated. The potential deal remains subject to Yieldbroker stockholder approval, final definitive documentation, and would be subject to customary closing conditions and regulatory reviews."

18:09 EDT Vornado to postpone dividends until year-end, approves $200M share buyback plan - Vornado Realty Trust announced that it will postpone dividends on its common shares until the end of 2023, at which time, upon finalization of its 2023 taxable income, including the impact of asset sales, it will pay the 2023 dividend in either (i) cash, or (ii) a combination of cash and securities, as determined by its Board of Trustees. Vornado also announced that, in order to enhance shareholder value, its Board of Trustees has authorized the repurchase of up to $200M of its outstanding common shares under a newly established share repurchase program. Cash retained from dividends or from asset sales will be used to reduce debt and/or fund share repurchases.

18:05 EDT First Bancshares increases dividend 5% to 22c per share - First Bancshares declared a cash dividend of 22c per share, a 5% increase over previous quarter, to be paid on its common stock on May 24, 2023 to shareholders of record as of the close of business on May 8, 2023.

18:02 EDT Meta Platforms says FX a headwind to advertising growth in international markets - Expects Reels to be neutral to revenue by end of 2023 or early 2024. Expects headcount growth in excess of 1%-2% in 2024. Says most of near term CapEx spend to be directed to AI projects. Says feels "quite good" about AI position. Says pleased with engagement trends on Facebook. Says has significantly improved cost structure over past six months. Expects to recognize further restructuring charges throughout the year.

17:57 EDT Howard Hughes discloses Pershing Square buys $4.40M in common stock - In a regulatory filing, Howard Hughes disclosed that Pershing Square bought 58.8K shares of its common stock on April 24th for $4.40M.

17:21 EDT AGBA Group Holding files to sell 17.77M ordinary shares for holders

17:14 EDT Methanex sees FY23 production 6.5M equity tonnes - Forecasted production for 2023 is approximately 6.5 million equity tonnes, excluding any production from G3. Actual production may vary by quarter based on timing of turnarounds, gas availability, unplanned outages and unanticipated events.

17:12 EDT Spirit Airlines CFO provides Q2 operational guidance - "For the second quarter 2023, we estimate our operating margin will range between 4.5 to 6.5 percent. In this demand environment, and with a declining fuel price in the second quarter of this year, the business at full utilization should be producing double digit operating margins. However, we continue to be hampered by NEO engine availability and pilot attrition issues that are preventing us from ramping up aircraft utilization. The NEO engine issues should improve as the year progresses but will likely remain a drag on utilization for the rest of the year. Also, pilot attrition levels have improved slightly from last year, but they are still volatile and they have not yet improved to the levels that we had hoped. Given these continued constraints, and our concerns about Air Traffic Control staffing, our capacity is heading towards to the lower end of our previous full year 2023 guide of 18 to 20 percent," said Scott Haralson, Spirit's Chief Financial Officer. "We expect to be profitable for the remainder of the year with margins improving each quarter. We also expect our full year CASM ex-fuel to be around 7.0 cents. CASM ex-fuel should decline throughout the year as we improve efficiency with CASM ex-fuel in the fourth quarter 2023 being in the high 6's."

17:01 EDT Aravive announces poster presentation at ASCO - Aravive announced the presentation of a poster featuring batiraxcept data in clear cell renal cell carcinoma at the upcoming American Society of Clinical Oncology 2023 Annual Meeting, being held June 2-6, 2023 in Chicago, Illinois and virtually. In addition, an abstract highlighting batiraxcept data in pancreatic adenocarcinoma was accepted for publication.

16:58 EDT Methanex increases dividend 6% to 18.5c per share - Methanex has approved a 6% increase in its quarterly dividend to 18.5c per share from 17.5c per share. The increased dividend will apply to the dividend payable on June 30 to holders of common shares of record on June 16.

16:48 EDT Sunoco LP raises quarterly distribution 2% to 84.2c per common unit - Sunoco LP announced that the Board of Directors of its general partner declared a quarterly distribution for the first quarter of 2023 of 84.2c per common unit or $3.368 per common unit on an annualized basis. The distribution will be paid on May 22, 2023 to common unitholders of record on May 8, 2023. Future distribution increases will be evaluated and announced annually in the first quarter, balancing SUN's financial metric targets and growth opportunities.

16:45 EDT Progress Acquisition receives noncompliance notification from Nasdaq - Progress Acquisition announced that the company had received a notice from the Listing Qualifications Department of Nasdaq stating that the company was not in compliance with Nasdaq Listing Rule 5250 because the company had failed to timely file with the SEC its annual report on Form 10-K for the fiscal year ended December 31, 2022. The notice provides the company with 60 days, or until June 20 to submit to Nasdaq a plan to regain compliance in accordance with Nasdaq's listing requirements. If the company's plan is accepted, Nasdaq may grant the company up to 180 days, or until October 18, for the company to regain compliance.

16:42 EDT Impinj falls 20% to $109.00 after Q1 earnings miss, below-consensus Q2 guidance

16:41 EDT Servotronics names Robert Fraass as CFO, succeeding Lisa Bencel - Servotronics announced that Robert Fraass has been appointed CFO of the company effective May 1. He replaces Lisa Bencel who will be leaving the company later in May to pursue other interests. Fraass most recently comes from Stark Technologies Group where he served as Senior Vice President of Finance - Corporate Controller & Treasurer. He has also held several executive finance roles of increasing responsibility at PostProcess Technologies, Ivoclar Vivadent, Integer and Integrys Energy Services.

16:40 EDT Idex Corp. to acquire Iridian for C$150M cash consideration - Idex Corp. announced it has entered into a definitive agreement to acquire Iridian Spectral Technologies for cash consideration of C$150M, subject to customary adjustments. The acquisition complements existing IDEX optical coating expertise, allowing IDEX to expand its core capabilities to support current and future markets. "This acquisition strongly supports our strategic growth plan," IDEX Chief Executive Officer and President Eric Ashleman said. "It expands our talent, technology and product portfolio in optical filters, enabling us to better compete in our core markets, and expand into new markets that we believe will drive profitable growth." Privately held and based in Ottawa, Ontario, Canada, Iridian expects fiscal year 2023 sales of approximately C$36M and EBITDA margin in the low 30s.

16:34 EDT O'Reilly Automotive reports comparable store sales increased 10.8%

16:32 EDT Service Properties reschedules release of Q1 financial results to May 8 - Service Properties Trust announced that it has rescheduled the release of its first quarter 2023 financial results, previously scheduled for Tuesday, May 9, 2023, to after the Nasdaq close on Monday, May 8, 2023. It will now host a conference call on Tuesday, May 9, 2023 at 10:00 a.m. Eastern Time, with President and Chief Investment Officer Todd Hargreaves and Chief Financial Officer Brian Donley discussing first quarter results.

16:29 EDT Meta Platforms says Q1 EPS would have been 44c higher excluding charges - Meta said: "In March 2023, we announced three rounds of planned layoffs to further reduce our company size by approximately 10,000 employees across the Family of Apps, FoA, and Reality Labs, RL, segments. In connection with these layoffs, we expect to incur total pre-tax severance and related personnel costs of approximately $1B, of which $523M was recognized during the first quarter of 2023 and the remaining charges will be substantially recorded by the end of 2023. Total restructuring charges recorded under our FoA segment were $934M and RL segment were $210M during the first quarter of 2023. Excluding these charges, our operating margin would have been four percentage points higher and our diluted EPS would have been 44c higher for the first quarter of 2023."

16:22 EDT Rand Capital raises quarterly dividend 25% to 25c per share - The dividend will be distributed on or about June 14, 2023, to shareholders of record as of May 31, 2023.

16:22 EDT Pioneer Natural names Rich Dealy next CEO - Pioneer Natural Resources announced that the Board of Directors has named Richard P. Dealy as the Company's next Chief Executive Officer, effective January 1, 2024. Dealy will replace current CEO Scott D. Sheffield, who will retire at the end of 2023. Sheffield is expected to continue to serve on the Board following his retirement. The Board also previously nominated Dealy for election to the Company's Board. Chairman Ken Thompson said, "Rich is the right leader to build on the strong foundation that Scott has established. He embodies the Pioneer culture, and now is the right time to implement the robust succession plan we have put in place. Scott has been a trailblazer in this industry, and he has guided Pioneer through multiple commodities and market cycles as well as recent macroeconomic challenges, including the pandemic. The Board is deeply grateful to Scott for his leadership over the years and respects his decision to retire in order to spend more time with his personal and philanthropic interests." Dealy is currently the Company's President and Chief Operating Officer.

16:17 EDT Interim analysis of Verastem's RAMP 201 trial to be presented at ASCO - Verastem Oncology "announced that an abstract highlighting updated interim results from Part A of the ongoing Phase 2, registration-directed RAMP 201 trial evaluating avutometinib and defactinib in patients with low-grade serous ovarian cancer has been selected for a presentation in a Poster Discussion Session at the upcoming American Society of Clinical Oncology Annual Meeting taking place June 2-6, 2023 in Chicago, IL. The objective of Part A of the RAMP201 LGSOC study was to determine the go forward regimen between avutometinib monotherapy or the combination of avutometinib and defactinib to be studied in Part B of the study. The efficacy and safety of each regimen were assessed in both KRAS mutant and KRAS wild-type recurrent LGSOC. The ongoing expansion Phase of the trial, which is fully enrolled, will evaluate the efficacy and safety of the regimen selected. The Company is in ongoing discussions with the U.S. Food and Drug Administration on confirmatory study plans and intends to provide an update after agreement with the FDA. Continued enrollment in the combination arm of RAMP 201 is planned to expand the clinical experience in anticipation of initiation of a confirmatory study."

16:16 EDT Meta Platforms says 'substantially completed' 2022 employee layoffs - Meta said: "In 2022, we initiated several measures to pursue greater efficiency and to realign our business and strategic priorities. As of March 31, 2023, we have substantially completed the 2022 employee layoffs while continuing to assess facilities consolidation and data center restructuring initiatives. We incurred additional pre-tax restructuring charges of $621M in the first quarter of 2023. In March 2023, we announced three rounds of planned layoffs to further reduce our company size by approximately 10,000 employees across the Family of Apps and Reality Labs segments. In connection with these layoffs, we expect to incur total pre-tax severance and related personnel costs of approximately $1B, of which $523M was recognized during the first quarter of 2023 and the remaining charges will be substantially recorded by the end of 2023."

16:15 EDT Amerisafe reports Q1 net combined ratio 82.2% vs. 80.1% last year

16:14 EDT Meta Platforms up 9% in after-hours trading following Q1 report - Meta shares are up $19.30, or 9%, to $228.70 in after-hours trading ahead of the company's earnings call.

16:13 EDT ServiceNow sees Q2 subscription revenue $2.04B-$2.045B

16:13 EDT Meta reports Facebook MAUs of 2.99B as of March 31, up 2% year-over-year - Meta Platforms reports family daily active people, or DAP, was 3.02B on average for March 2023, an increase of 5% year-over-year. Family monthly active people, or MAP, was 3.81B as of March 31, 2023, an increase of 5% year-over-year. Facebook daily active users, or DAUs, were 2.04B on average for March 2023, an increase of 4% year-over-year. Facebook monthly active users, or MAUs, were 2.99B as of March 31, 2023, an increase of 2% year-over-year. In the first quarter of 2023, ad impressions delivered across its Family of Apps increased by 26% year-over-year and the average price per ad decreased by 17% year-over-year.

16:12 EDT Meta reports Facebook DAUs 2.04B on average for March, up 4% year-over-year

16:09 EDT Roku, Instacart announce partnership - Roku "announced a partnership with Instacart to help consumer-packaged goods advertisers make TV advertising more relevant and performance-driven across the entire streamer's journey. Across select pilot partners, results showed that on average, people who saw the ad on the Roku platform purchased more of the advertised products on Instacart versus the average customer. The partnership brings together viewership data from Roku, the #1 TV streaming platform in the U.S., Canada, and Mexico, and insights from Instacart, the leading grocery technology company in North America, for marketers to measure whether streamers are purchasing products on Instacart after seeing an ad on the Roku platform. By matching this data with Roku's first-party data, marketers can quantify the impact of TV streaming advertising on product sales - while keeping customer data from Instacart and Roku secure."

16:04 EDT Raytheon Technologies to supply data management tech to American Airlines - Raytheon Technologies' (RTX) Collins Aerospace business is partnering with American Airlines (AAL) to bring aircraft data management technology to improve the airline's safety, reliability and analytics. American is installing the Collins InteliSight on more than 500 aircraft, including its entire Boeing 737NG fleet and the majority of its Airbus A320s, with plans to install the device on its Boeing 777 fleet. The Collins Aerospace InteliSight AID captures, records, stores, encrypts, and sends aircraft data to Collins' ground platform, GlobalConnect. American installed the InteliSight AID on more than 200 aircraft in six months, capturing, securing, and offloading data from more than 100,000 flights. American is currently performing the installation of the Collins AID at seven American Airlines locations.

15:45 EDT Old Dominion shares fall almost 11% after reporting Q1 results - Shares of Old Dominion are down 10.4% or $35 per share to $304.19 after reporting Q1 results that missed consensus estimated on the top and bottom lines. Greg C. Gantt, President and Chief Executive Officer of Old Dominion, commented, "Old Dominion's first quarter financial results reflect continued softness in the domestic economy and a challenging operating environment. The resulting decrease in our volumes contributed to our first decline in quarterly revenue and earnings per diluted share in over two and a half years. The decrease in LTL revenue included an 11.9% decrease in LTL tonnage per day that was partially offset by a 9.2% increase in LTL revenue per hundredweight. The combination of this decrease in revenue and slight deterioration in our operating ratio contributed to the 0.8% decrease in earnings per diluted share to $2.58 for the quarter. "Our daily tonnage decreased during the first quarter due to decreases in LTL shipments per day and LTL weight per shipment of 9.6% and 2.5%, respectively. While our volumes decreased on a year-over-year basis, our overall market share remained relatively consistent and our yield continued to improve. LTL revenue per hundredweight, excluding fuel surcharges, increased 8.6% due primarily to the ongoing execution of our yield-management strategy. We remained disciplined throughout the first quarter and continued to focus on our consistent, cost-based approach to managing yields and individual account profitability. In support of this strategy, we also continued to provide superior service to our customers that included 99% on-time service and a cargo claims ratio of 0.1%. Publicly traded companies in the space include ArcBest (ARCB), J.B. Hunt (JBHT), Knight-Swift (KNX), Old Dominion (ODFL), Swift Transportation (SWFT) and Werner (WERN).

14:59 EDT Shares of Teck Resources advance after withdrawal of reorganization plan - Shares of metals and mining exploration firm Teck Resources (TECK) are up 3.25% or $1.40 per share to $44.60 in afternoon trading on Wednesday, after the firm withdrew its plan to split into two entities, ahead of a shareholder vote, as the miner looks to end the $22.5B takeover attempt from Glencore (GLNCY). Shares of Glencore are also up over 3% at the time of writing.

14:57 EDT Editas Medicine treatment of sickle cell disease granted FDA orphan status - Editas Medicine's treatment of sickle cell disease was granted FDA orphan status, according to a post to the agency's website. Reference Link

14:40 EDT First Republic halts for volatility as report says Fed borrowing may be curbed - Shares of First Republic were down $2.00, or 25%, to $6.10 when the stock was halted for a circuit-breaker.

14:02 EDT Franklin Templeton Money Market Fund launches on Polygon blockchain - Franklin Templeton, a subsidiary of Franklin Resources, announced that the Franklin OnChain U.S. Government Money Fund, the first U.S.-registered mutual fund to use a public blockchain to process transactions and record share ownership, is now supported on the Polygon blockchain. Franklin Templeton continues to see operational efficiencies through use of a blockchain-integrated system, including increased security, faster transaction processing and reduced costs, benefiting Fund shareholders. The Fund's transfer agent maintains the official record of share ownership via a proprietary blockchain-integrated system that utilizes blockchain technology for transaction activity.

13:42 EDT Impac Mortgage trading halted, news pending

13:39 EDT Vertex announces U.S. FDA approval for expanded use of Trikafta - Vertex Pharmaceuticals announced the U.S. Food and Drug Administration approved the expanded use of Trikafta to include children with cystic fibrosis, or CF, ages 2 through 5 years who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator gene or a mutation in the CFTR gene that is responsive to Trikafta based on in vitro data. Trikafta was previously approved by the FDA for use in people with CF 6 years and older with at least one F508del mutation or a mutation in the CFTR gene that is responsive to Trikafta based on in vitro data, the company noted.

13:06 EDT Fox Corp. announces formation of Tubi Media Group - Fox Corporation announced the formation of the Tubi Media Group under the leadership of newly appointed CEO, Paul Cheesbrough. The new division will house FOX's standalone digital businesses - including Tubi, Credible and Blockchain Creative Labs - as well as the digital platforms and teams that underpin FOX's wider digital business in News, Sports and Entertainment. The creation of this division reflects the growing momentum of FOX's digital businesses and will provide the necessary strategy, leadership and focus to take them to the next level. Cheesbrough, who served previously as CTO and President of Digital for Fox Corporation, where he oversaw the acquisition and management of Tubi, will continue to be based in Los Angeles and report to Lachlan Murdoch, Executive Chair and CEO of Fox Corporation. Tubi Media Group will announce the new CEO for Tubi Streaming in the near future while Massoudi will remain through a transition period until the end of June.

12:53 EDT Fox Corp. announces formation of Tubi Media Group - Fox Corporation announced the formation of the Tubi Media Group under the leadership of newly appointed CEO, Paul Cheesbrough. The new division will house Foxs' standalone digital businesses - including Tubi, Credible and Blockchain Creative Labs - as well as the digital platforms and teams that underpin its digital business in sports, news and entertainment. "The creation of this division reflects the growing momentum of FOX's digital businesses and will provide the necessary strategy, leadership and focus to take them to the next level," the company said in a statement. "Our strategic acquisition of Tubi in 2020 established a cornerstone in our digital streaming strategy, which under Paul and Farhad's leadership has driven record growth and is now the clear market leader in AVOD in the US," said Lachlan Murdoch, Executive Chair and Chief Executive Officer, Fox Corporation. Tubi Media Group will announce the new CEO for Tubi Streaming in the near future while Farhad Massoudi will remain through the transition period until the end of June.

12:44 EDT Novartis announces positive opinion for Cosentyx in hidradenitis suppurativa - Novartis announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion and recommended granting a marketing authorization for Cosentyx in adults with active moderate to severe hidradenitis suppurativa.

12:22 EDT Aridis Pharmaceuticals receives Nasdaq notice on late filing of Form 10-K - Aridis Pharmaceuticals announced that it received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC on April 19, 2023 indicating that the company is not currently in compliance with Nasdaq's Listing Rules due to the company's inability to timely file its Form 10-K for the year ended December 31, 2022 with the SEC. The Notice has no immediate effect on the listing or trading of the company's securities. Pursuant to Listing Rule 5250(c)(1), the company was required to file the Form 10-K by April 17, 2023. The company previously reported its inability to file the Form 10-K by the Due Date in a Form 12b-25 that the company filed with the SEC on March 31, 2023. Under Nasdaq rules, a company that receives a delist determination for delinquency, can request an appeal to a Hearings Panel, pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series. A request for a hearing regarding a delinquent filing will stay the suspension of the company's securities only for a period of 15 days from the date of the request. In that regard, since the company is already before a Hearings Panel for its failure to comply with the $35 million minimum market value of listed securities requirement under Listing Rule 5550(b)(2), the company will have seven days, or until April 26, 2023, to request a stay of the suspension, pending a Hearings Panel decision. A Panel will review the request for an extended stay and notify the company of its conclusion as soon as is practicable, but in any event no later than 15 calendar days following the deadline to request a further stay. The company is working diligently to complete the Form 10-K. The company anticipates filing the Form 10-K as promptly as practicable.

12:03 EDT IMAX, Evo Entertainment Group partner for eight new IMAX locations - EVO Entertainment Group and IMAX Corporation announced a new partnership, agreeing to install eight new IMAX with Laser systems. This marks the first-ever collaboration between the two companies. As part of the agreement, EVO will bring seven new IMAX systems to Texas, including Houston and Austin, and one to Florida. The new systems are expected to begin opening in the third quarter of 2023.

12:01 EDT TFI International falls -9.2% - TFI International is down -9.2%, or -$10.58 to $104.45.

12:00 EDT First Republic falls -16.2% - First Republic is down -16.2%, or -$1.31 to $6.79.

12:00 EDT Fisker rises 19.6% - Fisker is up 19.6%, or 96c to $5.86.

11:56 EDT Ocugen treatment of ABCA4-associated retinopathies granted FDA orphan status - Ocugen's treatment of ABCA4-associated retinopathies was granted FDA orphan status, according to a post to the agency's website. Reference Link

11:51 EDT EzFill to effect 8-for-1 reverse stock split - EzFill Holdings announced it will effect a reverse stock split of its common stock. EzFill expects its common stock to begin trading on a split-adjusted basis on the Nasdaq Capital Market as of the commencement of trading on April 27, 2023. The reverse stock split was approved by the Board of Directors of the Company and is intended to increase the per share trading price of the Company's common stock to satisfy the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market. At the effective time of the reverse stock split, every 8 shares of EzFill common stock issued and outstanding will be combined into one share of common stock issued and outstanding. This will reduce the Company's outstanding common stock from approximately 28.8 million shares to approximately 3.6 million shares. No fractional shares of common stock will be issued as a result of the reverse stock split and instead fractional shares will be rounded up.

11:33 EDT Unitil appoints Robert Hevert as president, CAO, Daniel Hurstak as CFO - Unitil announced that its Board of Directors has approved several corporate organizational changes, all of which are effective as of May 1, 2023. Thomas Meissner, Jr., currently the Company's Chairman of the Board, CEO and President, will remain as the Company's Chairman of the Board and CEO, and Robert Hevert, currently the Company's SVP, CFO and Treasurer, will assume the newly created position of President and Chief Administrative Officer. Daniel Hurstak, currently the Company's Chief Accounting Officer and Controller, will assume Hevert's former position as SVP, CFO and Treasurer. Todd Diggins, currently the Company's Director of Finance, will assume Hurstak's former position as Chief Accounting Officer and Controller. Mr. Hevert, Mr. Hurstak and Mr. Diggins will each step down from their current roles in conjunction with these changes on May 1, 2023.

11:29 EDT Rogers, SpaceX announce agreement to bring satellite-to-phone coverage - Rogers Communications and SpaceX announced the companies have agreed to bring satellite-to-phone coverage nation-wide in Canada. Rogers and SpaceX will offer satellite-to-phone technology in Canada using SpaceX's Starlink low earth orbit satellites and Rogers national wireless spectrum. The companies plan to start with satellite coverage for SMS text and will eventually provide voice and data across the country's most remote wilderness, national parks and rural highways that are unconnected today, they said in a statement.

11:03 EDT American Water increases quarterly dividend 8% - American Water Works Company announced that its board declared a quarterly cash dividend payment of 70.75c per share of common stock, an increase of 8%. The company expects to continue its dividend growth within a 7%-9% range over the long term, with a target dividend payout ratio of between 55%-60% of earnings. The increased quarterly dividend will be payable on June 1, to all shareholders of record as of May 9.

11:00 EDT Infosys, Walmart Commerce Technologies partner for omni-channel solutions - Infosys (INFY) announced a new collaboration with Walmart Commerce Technologies (WMT) to help retailers leverage technology solutions that simplify customer and sore employee experiences. Infosys will help retailers implement and use Store Assist, which enables them to provide seamless omnichannel experiences such as pickup, delivery and ship from store for both employees and customers.

10:44 EDT Activision calls CMA decision 'irrational and inconsistent with the evidence' - As announced on January 18, 2022, Microsoft (MSFT) plans to acquire Activision Blizzard (ATVI) for $95 per share in an all-cash transaction. Today, the United Kingdom Competition and Markets Authority announced a decision to block the merger, stating that competition concerns arose in relation to cloud gaming and that Microsoft's remedies addressing any concerns in cloud gaming were not sufficient. In its earnings release this morning, Activision said, "Activision Blizzard considers that the CMA's decision is disproportionate, irrational and inconsistent with the evidence. Microsoft has announced its decision to appeal the CMA's ruling, and Activision Blizzard intends to fully support Microsoft's efforts on this appeal. Activision Blizzard continues to believe that the deal is pro-competitive, will bring Activision Blizzard content to more gamers, and will result in substantial benefits to consumers and developers in the UK and globally. The parties continue to fully engage with other regulators reviewing the transaction to obtain any required regulatory approvals."

10:39 EDT Boeing CEO: Certification timelines for 777x, Max, Max 10 intact

10:35 EDT Agenus to present Phase 1, Phase 2 trial data at ASCO meeting - Agenus announced plans to present clinical data at the American Society of Clinical Oncology 2023 Annual Meeting, to be held June 2-6 in Chicago, IL. Data from a single-arm, open-label Phase 2 study of balstilimab and zalifrelimab plus doxorubicin in patients with advanced sarcomas will be presented at an oral session on Monday, June 5 from 11:30am - 2:30pm CDT. Complete results from the monotherapy arm of the first-in-human dose escalation study of AGEN2373 in patients with advanced solid tumors will be presented at a poster discussion on Saturday, June 3rd from 3:00pm - 4:30pm CDT.

10:34 EDT Boeing will continue to work transparently with FAA, customers, says CEO

10:34 EDT Novartis to present Kisqali Phase III NATALEE trial data at ASCO - Novartis announced it will present new data from its oncology portfolio at the 2023 American Society of Clinical Oncology, or ASCO, Annual Meeting, including from more than 40 Novartis-sponsored and investigator-led trials. Primary results from the NATALEE trial evaluating Kisqali plus endocrine therapy, which the firm calls "the first and only positive Phase III study of a CDK4/6 inhibitor in a broad population of patients with stage II and III HR+/HER2- early breast cancer at risk of recurrence, including those with no nodal involvement," will be presented. "We look forward to sharing the primary analysis from the Phase III NATALEE trial of Kisqali in the investigational setting in a broad population of patients with early-stage breast cancer at ASCO. These promising data, together with other key updates, illustrate how we continue to advance our pipeline in oncology, with the potential to help address the significant unmet needs of patients living with cancer," said Shreeram Aradhye, M.D., President, Global Drug Development and Chief Medical Officer, Novartis.

10:13 EDT Aurora Cannabis partners with Strainprint for tracking program - Aurora Cannabis announced the launch of a new tracking program designed to support and empower cannabis patients on their wellness journey. Alongside the advice of a healthcare professional, Aurora patients can use Strainprint App journal to track their medical cannabis journey by logging their symptoms and consumption habits to better understand which strains, THC and CBD levels, ingestion methods and doses best work for them. Patients can also explore new products, learn more about strains and understand what has helped other patients through the App. All data entered and gathered by the Strainprint App is anonymous and aggregated.

10:10 EDT Biofrontera announces last patient completion in Phase I study of Ameluz - Biofrontera announced that that the last patient in a Phase I study to evaluate the safety and tolerability of Ameluz - PDT for treatment of mild to severe actinic keratosis on the face and scalp in the expanded treatment field using 3 tubes of BF-200 ALA 10% gel has now completed the study. This Phase 1 clinical study is being conducted by Biofrontera Bioscience GmbH, a wholly owned subsidiary of Biofrontera AG. Top line results from the study are expected in the fourth quarter of 2023.

10:08 EDT Allogene to present Phase 1 Data from ALLO-501/501A trials at ASCO - Allogene Therapeutics announced it will present updated data from the Phase 1 ALPHA/ALPHA2 trials of ALLO-501/501A at the American Society of Clinical Oncology, or ASCO, Annual Meeting June 2-6. The ALPHA/ALPHA2 trials were designed to assess the safety, tolerability, and preliminary efficacy at increasing dose levels of ALLO-501 and ALLO-501A, allogeneic CAR T cell product candidates that target CD19. In addition to exploring cell doses, these studies evaluated escalating doses of ALLO-647, Allogene's proprietary lymphodepleting antibody designed to prevent premature rejection of AlloCAR T cells. Allogene is currently enrolling the potentially pivotal Phase 2 ALPHA2 trial of ALLO-501A in large B cell lymphoma, or LBCL. "We are looking forward to sharing updated data from our Phase 1 ALPHA/ALPHA2 trials. Prior updates from the ALPHA/ALPHA2 trials provided clear proof-of-concept for the ability of an allogenic CAR T product candidate to induce deep and durable responses in LBCL, a crucial finding as we seek to establish a new era in CAR T," said Zachary Roberts, M.D., Ph.D., Executive Vice President, Research & Development and Chief Medical Officer.

10:07 EDT Theseus Pharmaceuticals to present data from Phase 1/2 THE-630 trial - Theseus Pharmaceuticals announced that initial dose escalation data from the ongoing phase 1/2 study of THE-630 in advanced gastrointestinal stromal tumors were accepted for online publication at the 2023 American Society of Clinical Oncology Annual Meeting, taking place June 2-6, in Chicago, Illinois. The abstract selected for online publication was submitted on February 14, 2023. On May 25, 2023, Theseus plans to host a virtual investor event to present data with an updated cutoff date. The data to be presented from the ongoing dose escalation study are expected to include preliminary safety, pharmacokinetic, and clinical activity data through cohort 6, as well as an analysis of circulating tumor DNA data through cohort 5. THE-630 is a pan-variant tyrosine kinase inhibitor of the receptor tyrosine kinase KIT, designed for patients with GIST that have developed resistance to earlier lines of therapy. The primary objectives of the phase 1 dose escalation portion of the study are to evaluate the safety profile of THE-630, including the determination of a recommended phase 2 dose in GIST patients who have received imatinib and at least one other TKI. Secondary objectives include determining the PK profile of THE-630, and to characterize preliminary evidence of antitumor activity.

10:06 EDT Zentalis to present clinical data from Phase 1b trial of azenosertib - Zentalis Pharmaceuticals announced today that it will present positive clinical data from its Phase 1b trial investigating azenosertib in combination with chemotherapy in patients with advanced platinum-resistant ovarian cancer in a poster at the American Society of Clinical Oncology Meeting in Chicago, June 2-6, 2023. Azenosertib is the Company's potentially first-in-class Wee1 inhibitor currently being investigated in multiple clinical trials as a monotherapy and in combination. The poster, entitled "Correlation of Cyclin E1 expression and clinical outcomes in a Phase 1b dose- escalation study of Azenosertib, a Wee1 inhibitor, in combination with chemotherapy in patients with platinum-resistant or refractory epithelial ovarian, peritoneal, or fallopian tube cancer," will be presented on June 5, 2023, from 1:15 PM-4:15 PM CT and the poster discussion session will be on June 5, 2023, from 4:30 PM-6:00 PM CT. "We are pleased to have the opportunity to share these exciting clinical data from our chemotherapy combination trial at ASCO this year. These encouraging clinical data, together with the preclinical data we recently presented at the 2023 AACR Annual Meeting, provide clear support for the use of Cyclin E1 expression as a predictive marker to identify patients who may significantly benefit from treatment with azenosertib," said Kimberly Blackwell, M.D., Chief Executive Officer of Zentalis. "Importantly, these findings offer robust evidence that azenosertib restores chemotherapy sensitivity in Cyclin E1 positive cancers, which are known to be chemotherapy resistant.

10:03 EDT Bolt Biotherapeutics to present BDC-1001 trial data at 2023 ASCO meeting - Bolt Biotherapeutics (BOLT) announced that it will present a poster with clinical data from its completed Phase 1 dose-escalation study of BDC-1001 at the 2023 American Society for Clinical Oncology Annual Meeting. BDC-1001 is an investigational Immune-Stimulating Antibody Conjugate in development for the treatment of patients with HER2-expressing cancer. The ASCO presentation will include comprehensive results from the company's Phase 1 single-agent and combination dose-escalation trial of BDC-1001 that enrolled more than 100 patients. "We look forward to presenting a comprehensive data set at ASCO that provides detailed safety, efficacy, pharmacokinetic and pharmacodynamic results from our recently completed Phase 1 dose-escalation trial evaluating BDC-1001 as a single agent and in combination with nivolumab," said Edith A. Perez, M.D., Chief Medical Officer of Bolt Biotherapeutics. "These data support the recommended Phase 2 dose and schedule for BDC-1001. We are making steady progress towards initiating two Phase 2 studies in 2023 evaluating BDC-1001 in multiple single-agent solid tumor settings, and in combination with nivolumab supplied by our partner BMS and with pertuzumab supplied by our partner Roche (RHHBY)."

10:02 EDT Blueprint Medicines to present new clinical data at 2023 ASCO meeting - Blueprint Medicines announced the acceptance of clinical abstracts for multiple programs across its precision therapy portfolio at the 2023 American Society of Clinical Oncology Annual Meeting, June 2 to 6. The presentations showcase Blueprint Medicines' next wave of therapeutic candidates in its clinical pipeline, and highlight ongoing progress as the company seeks to pioneer innovative combination strategies and advance development of its programs into earlier lines of treatment, the company said. The datasets to be reported at the ASCO Annual Meeting include: Results from the ongoing dose escalation part of the VELA trial of BLU-222 in breast cancer and other cancers vulnerable to CDK2 inhibition, showing evidence of monotherapy safety and pathway modulation. Updated results from the dose escalation part of the SYMPHONY trial showing the safety and tolerability of BLU-945 as a monotherapy and in combination with osimertinib in patients with late-line, EGFR-mutant non-small cell lung cancer. Results from the ongoing dose escalation part of the CONCERTO trial of BLU-451 in EGFR exon 20 insertion-positive NSCLC showing early safety and clinical activity.

10:00 EDT Evercore falls -7.2% - Evercore is down -7.2%, or -$8.64 to $110.99.

10:00 EDT First Republic falls -15.7% - First Republic is down -15.7%, or -$1.27 to $6.83.

10:00 EDT PROG Holdings rises 15.7% - PROG Holdings is up 15.7%, or $4.03 to $29.63.

09:52 EDT Sunrise New Energy announces 37,600 metric ton graphite anode order from BYD - Sunrise New Energy (EPOW) announced BYD (BYDDF) as a new customer with the commencement of shipments under a 37,600 metric ton graphite anode purchase order, which is valued at $225M based on recent pricing for graphite anode. Sunrise has increased its annual production capacity to 20,000 tons at the end of 2022. The Company expects to achieve further increases in production capacity this year and to complete fulfillment of this purchase order by the middle of 2024.

09:47 EDT TFI International falls -8.8% - TFI International is down -8.8%, or -$10.11 to $104.92.

09:47 EDT Wabash rises 14.6% - Wabash is up 14.6%, or $3.25 to $25.43.

09:47 EDT Vertiv Holdings rises 21.5% - Vertiv Holdings is up 21.5%, or $2.63 to $14.86.

09:40 EDT First Republic trading resumes

09:32 EDT Siemens, Infinite Acres sign MoU to jointly open research center - Siemens Netherlands and Infinite Acres are one step closer to building a vertical farming Field-Lab and Experience Center in The Hague, featuring Siemens technology and services. The two companies have signed a Memorandum of Understanding in which they agreed to jointly open a multi-part research center at Infinite Acres' headquarters in The Hague. In this research center, the companies will integrate Siemens' state-of-the-art hardware and software with Infinite Acres' operating platform and controlled environment growing technology, as well as learnings from Infinite Acres research and development facilities in the United States. The result: advancing the ability for Infinite Acres global breeding and technology partners to expedite the development of the vertical farming industry. With this, both parties are committed to develop sustainable, eco-friendly, and healthy food cultivation solutions across the U.S. and the world.

09:22 EDT Tomi Environmental comments on proposed EPA restrictions on EtO exposure - TOMI Environmental Solutions commented on the Environmental Protection Agency's recent proposed restrictions to limit Ethylene Oxide exposure. The company said, "Approximately 20 billion medical devices are sterilized per year with EtO, and restricting its usage could create a significant market void that may be filled with alternative sterilization processes such as TOMI's patented Binary Ionization Technology Technology. The EPA is proposing to cut Ethylene Oxide emissions by 80% through the implementation of more stringent air emissions standards at 86 commercial sterilizer locations in the United States. Ethylene Oxide exposure has been linked to an increased risk of cancer, with the EPA's own analysis reporting an additional cancer risk between 1 in 36 and 1 in 10 for those who work with the chemical. EtO, a chemical disinfectant for pharmaceuticals and medical equipment, can sterilize medical products such as catheters, personal protective equipment, and pharmaceutical ingredients that would have been otherwise damaged or degraded by other high-temperature or steam sterilizations. TOMI's patented Binary Ionization Technology solution utilizes a low percentage hydrogen peroxide as its only active ingredient and uses patented ionized Hydrogen Peroxide technology in all SteraMist systems to create superior disinfection. TOMI's active ingredient leaves no residue, has decontamination efficacy upwards of 99.9999%, and takes 5 seconds to complete, a significant improvement from older technologies. Unlike other sterilization agents, SteraMist does not emit any carcinogenic byproducts, only oxygen and water. Additionally, SteraMist offers flexible storage and superior versality compared to EtO, which can be highly volatile. SteraMist validates against the gold standard for sterilization Geobacillus stearothermophilus spores."

09:17 EDT EzFill announces CEO McConnell to step down, Levy appointed interim CEO - EzFill announced Chief Executive Officer Mike McConnell has stepped down as CEO, effective immediately, to pursue other interests. At the same time, EzFill appointed co-founder Yehuda Levy as Interim CEO until a permanent successor is found. EzFill's Board of Directors has initiated a search for a new CEO. Levy is being considered for the full-time position. Yehuda Levy is one of EzFill's founders, who had the vision to start a mobile fueling company to service clients initially in Miami Beach back in 2016. EzFill also announced that it has named Miami-based tech entrepreneur Avi Vaknin as the Chief Technology Officer. Vaknin will be responsible for driving the company's technology strategy and overseeing the development of cutting-edge solutions for the mobile fueling sector.

09:15 EDT Volcon ePowersports announces expansion into Canada - Volcon announced its portfolio of electric vehicles will be available at Canadian dealerships, with industry veteran Gerry Picard being named the brand's Canadian National Sales Manager. Picard brings a strong knowledge of Canadian powersports dealership operations, having most recently served as Canadian Director of Sales for Mahindra Vehicle Sales and Service for its Roxor brand from 2018-2022. "We are excited to announce our expansion into Canada," said Melissa Coffey, Vice President of Global Revenue and Business Development at Volcon. "It's an important market for our growing line of 2-wheel and 4-wheel products and a natural extension of our efforts in the U.S. We are also thrilled to name Gerry Picard as our head of sales in Canada. He brings decades of experience in helping dealership owners grow their business and we're glad to have him represent our brand in Canada."

09:10 EDT Borqs send letter to shareholders regarding divestment of solar subsidiary - Borq Technologies CEO Pat Chan wrote the following letter to shareholders. "The purpose of this letter is to help clarify the proposed divestment of our company's ownership in Holu Hou Energy and the implications that this transaction may have to Borqs and our shareholders... As we have stated in prior press releases, the Committee on Foreign Investment in the United States has notified our company by a letter dated December 13, 2022, that CFIUS has identified risks to US national security arising as a result of Borqs's investment in HHE... In efforts to address the national security concerns of CFIUS, we have signed a National Security Agreement with CFIUS identifying all the steps that Borqs shall take in order to completely remove Borqs' involvement with HHE, including the transfer of our ownership in HHE into a Divestment Trust which is now under the supervision of an independent trustee.... Since Borqs' financial support of HHE, which began with the acquisition of HHE in October 2021, HHE has signed multiple contracts with customers in Hawaii for the deployment of HHE's solar energy plus storage system and EnergyShare technology for Multi-Dwelling Residential Units such as the recently announced Lendlease Island Palm Communities in Honolulu for large military personnel housing compounds. Installations for these projects are to begin this summer and when completed will be worth well into nine figures in sales for HHE which will possibly translate to a very significant amount in the divestment of the HHE interests by Borqs... With HHE's successful business expansion just in the State of Hawaii, we are certain that HHE will have a bright future in other densely populated states with plentiful sunlight such as California... We intend to comply with all of the requirements of the US government. The divestment, when completed, is expected to provide a large liquidity position to Borqs, and management may seek approval from the Board of Directors to allocate an appropriate amount for buy back of our outstanding ordinary shares from the market. We believe the current market price is not reflective of the correct value of the Company.

09:06 EDT Tremor International launches self-service cross-platform planner - Tremor International announced the launch of its first-to-market self-service cross-platform planner that solves for the fragmentation of linear and digital viewership. The planner's technology enables broadcasters to maximize reach and frequency allocation holistically across linear and digital inventory, and provides advertisers and agencies with optimized, actionable cross-screen media plans. Major broadcasters and agencies are engaged in extensive testing with the planner.

09:05 EDT Inhibrx begins registration-enabling trial of AATD candidate, resumes Phase 1 - Inhibrx has initiated a registration-enabling trial for INBRX-101, an optimized recombinant human AAT-Fc fusion protein, for treatment of patients with emphysema due to alpha-1 antitrypsin deficiency - AATD -. Additionally, the company announced that the FDA has lifted the partial clinical hold on studies evaluating its death-receptor 5 agonist, INBRX-109. The ElevAATe trial is designed as a randomized, controlled, double-blind, head-to-head superiority study examining INBRX-101 against plasma-derived AAT. The primary endpoint of the trial is the mean change in the average functional AAT concentration. The initial read-out from the ElevAATe trial is expected to occur in late 2024. In March 2023, the Company announced the pause in patient enrollment for the INBRX-109 trials as a result of the pre-defined stopping rules built into the Phase 2 protocol. In April 2023, the FDA lifted the partial clinical hold. Patient enrollment is expected to resume next month. Phase 1 combination cohorts are expected to begin reading out by the end of 2023 and data from the registration-enabling trial in unresectable or metastatic conventional chondrosarcoma is expected during the second half of 2024.

09:04 EDT Bit Origin announces production, operation update for January to March - Bit Origin provided its production and operation update for January 2023 to March 2023. Operation Update: Since December 2022, the Company gradually moved out all of its crypto currency mining equipment from its mining facility in Georgia, and the Company redeployed its mining equipment in the Indiana mining facility. As of March 31, 2023, the total mining hash rate stands at 403 PH/s with 4,250 miners installed in the Indiana facility, representing all miners the Company has purchased. Bitcoin Production and Revenue: The Company mined 86.4 Bitcoins and achieved a revenue of US$1,975,202 in the first quarter of 2023. As of March 31, 2023, the Company has one hosting mining site in operation and one mining site under development. The Company ceased its operation in the mining facility in Georgia from December 31, 2022. Site One - Marion, IN, 5.3 Megawatts: On June 8 and July 11, 2022, the Company announced that it entered into two hosting service agreements to increase mining capacity by 3 MW and 2.3 MW, respectively. Based on mutual understanding and arrangements, the Company further expanded its capacity in the Indiana mining facility, and as of March 31, 2023, 4,250 miners at this site have been deployed. Site Two - Cheyenne, WY, 45MW: On June 15, 2022, the Company announced that it entered into a set of definitive agreements with a private cryptocurrency mining investment fund. As of March 31, 2023, Phase I of the Project of a capacity of up to 45MW for the mining facility in Wyoming is energized.

09:02 EDT Imperial Petroleum announces full repayment of outstanding loans - Imperial Petroleum recently repaid early and in full its sole remaining loan with a $16.0 million outstanding balance from Alpha Bank. This loan was secured with first priority mortgages on product tankers Clean Nirvana and Clean Justice. Following the recent early repayment of all outstanding debt - approximately $69 million in total, the Company's fleet of twelve vessels is now completely unencumbered. The repayment of all indebtedness will save approximately $10.3 million per annum in principal loan repayments and about $5 million per annum in finance costs basis current level of LIBOR rates. The combination of a high cash balance and unencumbered fleet, positions the Company well for future growth.

09:01 EDT LiqTech signs distribution agreement with Silicon Filter in China - LiqTech and Silicon Filter, a China-based company focused on providing technologies for chemical applications, have entered into a distribution agreement to supply LiqTech's advanced filtration systems for phosphoric acid purification in China. Silicon Filter specializes in commercializing industrial technologies for process design and operations optimization into various production processes for the chemical industry.

08:47 EDT Camber Energy terminates all warrants in favor of Discover, Antilles - Camber Energy entered into agreements canceling and terminating, effective as of the agreement date, one hundred percent of the warrants held by Discover Growth Fund and Antilles Family Office. The Termination Agreements also include a provision granting the Company the right to redeem the remaining shares of Series C Preferred Stock held by Antilles, subject to the conditions set out therein. Prior to entering into the Termination Agreements Camber had already extinguished, through redemptions and conversions, approximately ninety-four percent of previously issued shares of Series C Preferred Stock.

08:45 EDT Bebuzee reports influx of registrations by real estate agents, tradesmen - Bebuzee that, since the relaunch of last week's enhanced www.Bebuzee.com, the platform has gained thousands of real estate agent and tradesmen registrations daily, positioning Bebuzee to become the largest digital real estate platform by this time next year.

08:42 EDT SharpLink Gaming announces revised date for 2023 Annual Meeting - SharpLink Gaming announced that the date for the Company's 2023 Annual General Meeting of Shareholders, originally scheduled to be held on Friday, May 26, 2023, has been moved to Thursday, May 25, 2023. All other details remain unchanged. In consideration of the fact that May 26, 2023 immediately precedes the Memorial Day holiday weekend, the Company's Board of Directors has elected to reschedule the Meeting as a convenience for SharpLink shareholders.

08:42 EDT Capstone in deal with Texas energy firm for C800S microturbines - Capstone Green Energy announced that its southern U.S. distributor, Lone Star Power Solutions, has contracted with a large West Texas energy company to provide an additional C800S Signature Series microturbine following a 3.6 MW Energy-as-a-Service EaaS contract earlier this year.

08:41 EDT Centogene launches FilterTool application as accessory to CentoCloud pipeline - Centogene announced the launch of FilterTool, an advanced web-based application for genetic data interpretation. The new FilterTool application seamlessly integrates with CENTOGENE's CE-marked Software as a Service bioinformatics pipeline, CentoCloud, as an accessory and enables laboratories, medical experts, and bioinformaticians to efficiently display, filter, select, and classify relevant genetic variants identified by Next Generation Sequencing data analysis. This will allow CentoCloud users to visualize key genetic variants of concern for any given patient. "At CENTOGENE, we deliver data-driven, life-changing answers to accelerate precision medicine, and this latest application release is the embodiment of our mission," said Prof. Peter Bauer, CENTOGENE's Chief Medical and Genomic Officer. "The new FilterTool application is an innovation that was designed by physicians, for physicians, and when combined with CentoCloud(R), significantly accelerates genetic variant interpretation. Ultimately, this paves the way to enhanced diagnostics and supports breakthrough discoveries."

08:38 EDT Duck Creek Technologies selected by Novo Insurance - Duck Creek Technologies announces that it has been selected by Silicon Valley telematics startup, Novo Insurance, as its technology platform of choice for policy, billing, insights, and data hub solutions. Duck Creek OnDemand enables Novo Insurance to bring its auto insurance products to market more quickly using its low-code and configurable open architecture platform. "Novo is quickly bringing auto insurance innovations to US consumers using their rich location-based technology," said Jess Keeney, Chief Product and Technology Officer Duck, Creek Technologies. "As a start-up operation, Novo Insurance recognized that Duck Creek's modern cloud solutions are market-leading and trusted. With simplified low-code configuration, they saw that we will get them where they want to be across their US and global markets quickly and efficiently."

08:37 EDT Entera Bio announces Goldstein joins its clinical, scientific advisory board - Entera Bio announced that Steven Goldstein, MD, Professor of Obstetrics and Gynecology at New York University School of Medicine and former President of The International Menopause Society, the North American Menopause Society and recipient of the Clarkson Award from NAMS for lifetime achievement in menopause research will be joining its Clinical and Scientific Advisory Board, CSAB. "We are thrilled to welcome Dr. Goldstein, a world-renowned leader in menopause and women's health, to our CSAB and look forward to working with him along with our esteemed endocrinology experts at this critical time for our EB613 program. Gynecologists remain primary care for the millions of women in or post-menopause globally and the importance of actively managing bone health is paramount to their well-being. As potentially the first oral osteoanabolic therapy for post-menopausal women, EB613 is being developed to fulfill this promise," stated Miranda Toledano, Chief Executive Officer of Entera.

08:36 EDT ArcelorMittal publishes 2022 Integrated Annual Review - ArcelorMittal ('the Company') has today published its 2022 integrated annual review. The company said, "The review, which can be accessed here - annualreview2022.arcelormittal.com - underpins the Company's commitment to transparent reporting and is a key pillar in our commitment to engage stakeholders and communicate our financial and non-financial performance. It provides an overview of the Company's performance in 2022, outlines progress against its strategic priorities, and details its short- and long-term goals and current action plans. We strive to reflect the guiding principles of the most respected and influential organisations and frameworks. In our 2022 review, we have started to align our reporting with the concepts and principles set out by the Corporate Sustainability Reporting Directive. We have also considered the recommendations and principles of the Task Force on Climate-related Financial Disclosures in preparing our integrated reporting. Our aim is to show our stakeholders how we are organised and how our management systems are set up to meet the requirements, what improvements we are making to respond to changes, what the challenges and opportunities are to deliver the strategy and measurable progress we have been making to achieve the strategic objectives. The result, we believe, is a more structured, direct and balanced review."

08:35 EDT ODP Corporation expands relationship with Microsoft - ODP Corporation (ODP) announced that it is expanding its longstanding relationship with Microsoft (MSFT) to include Microsoft Azure OpenAI Service advanced artificial intelligence technology to enhance customer experience, drive operational efficiencies, and more effectively pursue growth opportunities. Recognizing Azure's immense potential, ODP has been working with Microsoft to migrate legacy systems and to build out its customer-facing platforms, including its Varis digital procurement ecosystem and Business Central integration, on Microsoft Azure. This collaboration has enabled ODP to leverage the power of Azure's scalable cloud infrastructure, improving the speed, reliability, and security of its online services and applications.

08:34 EDT Logiq acquires Park Place Payments in transaction valued over $6M - Logiq has acquired Park Place Payments, a fintech company delivering innovative merchant payment solutions and adjacent financial services to SMBs through a nationally distributed local sales force. The company said, "Park Place is at the forefront of the booming gig economy, recruiting, training and motivating its independent account executives through a virtual workplace and online community. The company provides its sales force a unique opportunity to build an unlimited recurring income stream without any financial commitment. Over a relatively short period of time, this network of now more than 1,500 account executives has grown Park Place's annualized transaction volume to more than $180 million, from which Park Place expects to generate more than $5 million in revenue and positive cash flow this year." Logiq acquired Park Place as a wholly owned subsidiary in an all-stock transaction valued at more than $6 million after the achievement of certain milestones.

08:34 EDT Kopin receives $4.4M follow-on production order - Kopin announced that it received a $4.4M follow-on production qualification award from General Dynamics Land Systems for display systems for a major armored vehicle upgrade program. The upgrade program enables crews to identify enemy targets from farther away through the introduction of higher performance sensors and displays. The Kopin display systems provide significant enhancements over current generation sights to allow the full capability of the new sensors to be presented to the vehicle crew.

08:33 EDT Genasys selected by Santa Gruz, San Benito counties for SaaS contracts - Genasys announced Santa Cruz and San Benito counties have entered into new multi-year Genasys Protect software-as-a-service, SaaS, contracts. Genasys is providing public safety notification and evacuation management services for 30 California counties. Santa Cruz County has actively used Genasys Protect's Zonehaven evacuation management since the CZU Complex Fire in 2020. "The extension of the Genasys Protect platform in Santa Cruz County is the result of the exceptional performance of our Zonehaven software and support team during the severe weather," said Richard Danforth, Chief Executive Officer, Genasys, Inc. "This SaaS contract further expands the county's use of the Genasys Protect platform to enhance the safety of its 270,000 residents and 3 million annual visitors. With Genasys, the contiguous counties of Santa Cruz, San Benito, and Monterey will be able to more efficiently coordinate emergency notifications and evacuation management during regional crises."

08:23 EDT Energy Recovery gets $8M in contracts for desalination in Chile mining - Energy Recovery announced a collection of contracts totaling over $8M to supply PX Pressure Exchanger energy recovery devices and accessories to desalination facilities in Chile. These contracts are for mining applications and demonstrate the region's continuing investment in desalination. Chile is the world's No. 1 copper producer and the No. 2 producer of lithium. Industrial mines require fresh water for pumping minerals like lithium to the surface and for copper smelting. Combined, these commissioned desalination projects will provide over 350,000 cubic meters of water each day in this resource-rich, yet water-scarce South American nation. The PX is expected to prevent an estimated 140,000 tons of carbon emissions from entering the atmosphere each year. The orders are estimated to be fulfilled by Q4 2023.

08:20 EDT Xencor appoints Nancy Valente, M.D. as Chief Development Officer - Xencor announced the appointment of Nancy Valente, M.D., to Executive Vice President, Chief Development Officer. Dr. Valente has more than 20 years of experience in late-stage biopharmaceutical product development, and she most recently served as a senior vice president at Genentech, a member of the Roche Group, and as its global head and co-lead of global product development of its oncology and hematology therapeutic area.

08:17 EDT OpSec Group to become public through Investcorp Europe Acquisition I combination - OpSec Group and Investcorp Europe Acquisition I announced they have entered into a definitive business combination agreement that would result in OpSec Group becoming a public company. Upon closing of the proposed business combination, the newly combined company will operate as OpSec Group. The pro forma enterprise value of the combined company is approximately $426M. This transaction is supported by a $50M backstop by the sponsor of Investcorp Europe, with up to $199M in gross transaction proceeds available subject to redemptions by Investcorp Europe shareholders. Any incremental proceeds to be held on balance sheet, with current investors rolling 96% of their pro forma ownership. The transaction, which has been unanimously approved by the boards of directors of OpSec Group and Investcorp Europe, including a special committee of the board of directors of Investcorp Europe formed for the purpose of evaluating the transaction, is subject to approval by Investcorp Europe shareholders and other customary closing conditions, including the receipt of certain regulatory approvals and is expected to close in the second half of 2023.

08:14 EDT Transcode Therapeutics announces strategic expansion of product portfolio - TransCode Therapeutics announced a strategic expansion of its diverse product portfolio. New capabilities for TransCode's TTX delivery platform are embodied in the new provisional patent application entitled, "Nanoparticles Comprising Payloads and Their In Vivo Delivery." The technology disclosed in the '602 application represents an expansion of TransCode's therapeutic delivery platform to include applicability to gene editing by repairing and/or replacement of genes using CRISPR technology and cancer vaccines using messenger RNA. TransCode's CEO, Michael Dudley, said, "Our scientists have been working to expand the potential of our nanoparticle delivery system for some time in order to overcome the challenges of targeted delivery of therapies in oncology. We believe that by expanding our delivery platform and our resulting product portfolio including CRISPR, mRNA vaccines and potentially other targeted therapies outside of RNA positions the company as a platform delivery company." The filing of the '602 application directly supports TransCode's goal of deploying the right therapy for individual cancer patients. If issued, the proposed patent would join other granted patents controlled by TransCode, including US 9,629,812 and EP 2 961 386.

08:13 EDT Hoth Therapeutics Inc trading halted, news pending

08:11 EDT Immutep appoints Vogl as Chief Medical Officer - Immutep announces that Florian Vogl, M.D., Ph.D., MSc, has been appointed as Chief Medical Officer, CMO, with effect from 1 May 2023. Most recently, Vogl was CMO of Cellestia Biotech where he focused on delivering new treatments to patients with cancer and autoimmune disorders that had limited therapeutic options. Dr. Vogl assumes the CMO role from Frederic Triebel, M.D., Ph.D., who previously acted as both Chief Scientific Officer and CMO of Immutep. Dr. Triebel will now foremost focus on his responsibilities as CSO and as a member of Immutep's Board of Directors.

08:09 EDT Apollo Global announces formation of Apollo Clean Transition Capital - Apollo announced the formation of Apollo Clean Transition Capital, ACT Capital, an investment strategy that intends to redefine the capital market for climate solutions. ACT Capital seeks to meet the wide-ranging capital needs for the transition to clean energy and sustainable industry by providing competitive, flexible, and patient financing to the global market, supporting corporates in their transition to clean energy. The strategy launches with $4B in deployable capital from Apollo affiliates and strategic partners and will enable investment into a diversified global portfolio of yield and hybrid investments. "We believe ACT Capital is a premier financing solution for companies around the globe who require significant, flexible capital to support their energy transition efforts. We are thrilled to extend our long track record in this area and expand our commitment to driving a more sustainable future, recognizing the urgent need for climate capital deployment," said Apollo Co-President Scott Kleinman.

08:08 EDT LianBio announces results from Phase 3 EXPLORER-CN trial - LianBio announced positive topline results from the Phase 3 EXPLORER-CN trial investigating mavacamten for the treatment of Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy, oHCM. EXPLORER-CN met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in Valsalva left ventricular outflow tract, LVOT, gradient from baseline to week 30 compared to placebo. Safety results in the trial were consistent with previous studies of mavacamten in symptomatic oHCM, and no new safety signals were reported. The Phase 3 EXPLORER-CN trial enrolled a total of 81 patients in China with symptomatic oHCM. All participants had one measurable LVOT gradient greater than50 mmHg during screening."We believe the speed and quality with which the EXPLORER-CN trial was conducted is a testament to LianBio's ability to accelerate patient access to innovative medicines," said Yizhe Wang, Ph.D., Chief Executive Officer of LianBio. "I would like to acknowledge our team's hard work and commitment to the oHCM community and thank the EXPLORER-CN investigators and patients for their participation in this important study. With positive pivotal data now in hand and the NDA on file, we are optimistic about bringing mavacamten to market in China next year."

08:08 EDT Mobiquity Technologies integrates AI tech into ATOS 2.0 ad platform - Mobiquity Technologiesannounced the integration of AI technology into its ATOS 2.0 advertising platform, significantly improving the targeting of political ads. This development coincides with the start of the United States election season during which Mobiquity has noticed an increase in political ad campaigns using its AI targeting. As an increasing number of political organizations embrace digital advertising to connect with voters, Mobiquity's advanced targeting features are poised to become an indispensable tool for digital engagement.

08:06 EDT QSAM Biosciences receives second key patent in Europe for CycloSam - QSAM Biosciences announced that the European Patent Office, EPO, has allowed a key patent that protects the use of "lower specific activity" Samarium-153 in conjunction with the treatment of bone cancer in children and adults. This new patent in Europe covers the "high purity therapeutic bone agents" technology exclusively licensed to QSAM on a worldwide basis and relates to the novel manner in which the Samarium-153 is produced for use in CycloSam. "We believe that repeated dose regimens of CycloSam(R) may be the key to being able to successfully treat bone tumors, and we are continuing to advance our clinical trials program to generate data toward that goal," stated Douglas Baum, CEO and co-founder of the Company. "This allowance by the EPO marks our second patent in Europe, and we expect to register the patent in multiple individual countries in the EU over the following few weeks, thereby expanding our already established and robust patent estate. More so, this additional IP protection broadens our potential commercial market for what we believe may eventually be a breakthrough therapy for both primary and secondary forms of bone cancer," added Baum.

08:06 EDT Inovio: European COMP provides positive opinion on INO-3107 - Inovio announced that the European Committee for Orphan Medicinal Products has provided a positive opinion on Inovio's application for orphan drug designation in the European Union for INO-3107. INO-3107 is the company's product candidate that may contribute to the treatment of Recurrent Respiratory Papillomatosis. The opinion is now with the European Commission, which will provide a final decision on the application within 30 days.

08:04 EDT Paycor HCM acquiring behavioral science-based learning solution Verb - Paycor HCM will acquire Verb, a people development platform incorporating behavioral science and proprietary microlearning content to create workplace training. Paycor plans to fully integrate Verb into its HCM platform and accelerate the development of Paycor Paths, a new product designed to help organizations inspire behavior change within frontline leaders through a series of personalized development journeys. Paycor expects to fully integrate Verb's learning offerings into Paycor Paths by the second half of 2023.

08:03 EDT Alaska Air launches partnership with STARLUX Airlines - Alaska Airlines is celebrating its newest global airline partner: STARLUX Airlines, a Taipei-based premium carrier, which recently launched its inaugural transpacific service between Taipei and Los Angeles. Alaska is STARLUX's first airline partner.

08:02 EDT Blue Star Foods ramps shipments to Just Food For Dogs - Blue Star Foods announces it has ramped its shipments to Just Food For Dogs, under the initial 2023 contract for up to approximately $4 million revenue to Blue Star.

07:59 EDT CRH reports Q1 reported sales up 7% vs. last year - The company said, "In what is a seasonally quiet period for our business, the Group delivered a positive start to the year with first quarter sales and EBITDA ahead of the same period last year, driven by the successful execution of our integrated solutions strategy, resilient underlying demand, good commercial progress and the strong contribution from 2022 acquisitions. Americas Materials Solutions sales were 10% ahead of the same period in 2022, driven by robust pricing which more than offset the impact of unfavourable weather on activity levels in certain markets during this seasonally less significant quarter...Americas Building Solutions: First quarter sales were 22% ahead of the same period in 2022, reflecting good pricing progress, resilient underlying demand, the positive contribution from prior year acquisitions and the continued delivery of our integrated solutions strategy... Europe Materials: Like-for-like sales were 6% ahead of the same period in 2022 due to strong pricing momentum across all products and regions. Activity levels were impacted by less favourable weather conditions compared to the same period in 2022. Unfavourable currency translation effects resulted in total sales 1% behind 2022....Europe Building: First quarter sales were 1% behind the same period in 2022, reflecting a slower start to the year due to unfavourable weather and a strong prior year comparative."

07:55 EDT Boeing still expects to deliver 400-450 737s, 70-80 787s in 2023 - Sees FY23 CapEx ($1.5B). Comments taken from Q1 earnings conference call presentation slides.

07:47 EDT Lithium Americas CFO Eduard Epshtein retires, Pablo Mercado to succeed - Lithium Americas (LAC) announced the retirement of Eduard Epshtein and the appointment of Pablo Mercado as Executive Vice President and CFO to succeed Eduard as CFO of Lithium Americas. Upon completion of the planned separation of the Company's Argentine and North American businesses into two independent public companies, Pablo would become CFO of the North American business. Eduard will continue to work with Lithium Americas as an advisor supporting the Separation and the financial reporting needs of both businesses. Most recently, Mercado served as CFO of EnLink Midstream (ENLC).

07:36 EDT Boeing plans to ramp 787 production to five per month in late 2023 - On the 737 program, earlier this month the program's fuselage supplier notified Boeing that a non-standard manufacturing process was used on two fittings in the aft fuselage section of certain 737 airplanes. This is not an immediate safety of flight issue and the in-service fleet can continue operating safely. While near-term deliveries and production will be impacted as the program performs necessary inspections and rework, the program still expects to deliver 400-450 airplanes this year. On production, the supplier master schedule remains unchanged including anticipated production rate increases, which will result in higher inventory levels. The company expects final assembly production to recover in the coming months with plans to increase to 38 per month later this year and 50 per month in the 2025/2026 timeframe. The 787 program is producing at three per month with plans to ramp production to five per month in late 2023 and to 10 per month in the 2025/2026 timeframe. During the quarter, Commercial Airplanes secured net orders of 107. Also during the quarter the company secured commitments from Air India for 190 737 MAX, 20 787, and 10 777X airplanes and from Riyadh Air and Saudi Arabian Airlines for up to 121 787 airplanes. Commercial Airplanes delivered 130 airplanes during the quarter and backlog included over 4,500 airplanes valued at $334 billion.

07:34 EDT Boeing still expects to deliver 400-450 737 airplanes in 2023 - Plans to increase production to 38 per month later this year.

07:33 EDT Boeing CEO says 'demand is strong across our key markets' - "We delivered a solid first quarter and are focused on driving stability for our customers," said Dave Calhoun, Boeing president and CEO. "We are progressing through recent supply chain disruptions but remain confident in the goals we set for this year, as well as for the longer term. Demand is strong across our key markets and we are growing investments to advance our development programs and innovate strategic capabilities for our customers and for our future."

07:32 EDT Boeing reports total company backlog of $411B, including over 4,500 airplanes

07:31 EDT Boeing reports Q1 operating cash flow ($0.3B), free cash flow ($0.8B)

07:22 EDT Mindset Pharma files two patent applications for 'Family 6' - Mindset Pharma announced that it has filed two international patent applications under the Patent Coorperation Treaty, PCT, for the protection of certain of Mindset's non-hallucinogenic novel non-tryptamine compounds known as "Family 6." The filings are based on pre-clinical studies and provide Mindset with preliminary freedom to operate for all claimed drug candidates from Family 6. "By applying Mindset's innovative drug discovery and development platform on novel psychedelic-inspired non-hallucinogenic drug candidates, we have begun to see results. We believe that this class of drugs may have the potential to treat a substantially wider patient population including fragile population groups such as children or geriatric patients," said James Lanthier, CEO of Mindset Pharma. "Additionally, by reducing or removing the psychedelic effect, in-clinic supervision should not be necessary, in turn reducing cost and improving convenience of these treatment options."

07:20 EDT Cleveland-Cliffs reaches tentative labor pact with IAM for Middletown Works - Cleveland-Cliffs announced that it has reached a tentative agreement with the International Association of Machinists and Aerospace Workers IAM Local 1943 on a new 4-year agreement for its Middletown Works steelmaking operation. The contract will be effective on May 15, and will cover approximately 2,100 hourly employees. Lourenco Goncalves, Chairman, President and Chief Executive Officer of Cleveland-Cliffs said, "The new labor agreement with our valued IAM employees at Middletown represents another win-win for Cliffs and our union partners. We have a strong and loyal workforce as a result of these great relationships. Continued healthy partnerships like this one are the backbone of our future success, and we look forward to accomplishing our shared goals together." Middletown Works is an integrated steel operation with carbon steel melting, casting, hot and cold rolling, and finishing operations to produce a number of carbon and stainless steels for the automotive and other industries. The agreement is now pending ratification by IAM local union memberships.

07:19 EDT Carlyle Group appoints Cherwoo as independent director - Carlyle announced the appointment of Sharda Cherwoo, retired Ernst & Young senior partner, to serve as an independent director of its Board of Directors and a member of the Audit Committee of the Board, effective June 1, 2023. With this appointment, Carlyle's Board of Directors will comprise 13 members.

07:18 EDT Alkermes making 'meaningful progress' on oncology separation - Alkermes said its "continues to make meaningful progress on the previously announced planned separation of the company's oncology business." The separation "would allow Alkermes to maintain its focus on researching, developing and commercializing therapies for people living with complex neurological conditions and is expected to accelerate and enhance the profitability of the remaining neuroscience business," the company said in its earnings release. Alkermes continues to expect to complete the separation in the second half of 2023, subject to various customary conditions, including final approval from Alkermes' board of directors.

07:16 EDT Broadwind sends letter in connection with annual meeting of shareholders - Broadwind has sent a letter to shareholders in connection with its 2023 annual meeting of stockholders, which is scheduled to be held on May 23, 2023. "As the 2023 Annual Meeting of Stockholders approaches on May 23, 2023, we urge you to vote to support Broadwind, Inc.'s directors on the WHITE proxy card. Your vote will be especially important this year. An activist hedge fund, WM Argyle Fund has notified the Company that it intends to propose three nominees to the Company's Board of Directors. WM Argyle, which claims to be "one of Broadwind's largest shareholders" while only owning approximately 1% of Broadwind's outstanding common stock, appears to have been formed specifically to disrupt Broadwind. WM Argyle has made what we believe to be distorted, misleading and fundamentally false claims with respect to the Board and management team in a thinly veiled attempt to take control of Broadwind. WM Argyle is seeking to replace half of your independent Board, including the Chairman, the Chairman of the Audit Committee, and one of our most experienced technical and engineering experts. In stark contrast, WM Argyle's candidates are each worryingly unqualified... None of WM Argyle's candidates have ever served in a fidicuary role as a board member, ever. None of WM Argyle's nominees have backgrounds in clean technologies or energy transition manufacturing; none have senior executive or board experience; and none have senior-level financial expertise, or any such background required to be an effective director at Broadwind... All three of WM Arygle's nominees were employed at Bucyrus, a global mining company that was sold to Caterpillar in 2011. Despite WM Argyle's claims, this is not relevant experience to Broadwind: Bucyrus had significantly different products, structure, customers and end markets. WM Argyle's nominees, moreover, never served as senior operating or financial executives of Bucyrus, nor were they on its board of directors... Our directors have extensive experience as operating and financial executives and public company directors, with deep industry expertise in clean technologies and energy transition manufacturing, and broad backgrounds in sales and marketing, engineering, manufacturing, accounting, finance, law, M&A and risk management. Each director has been chosen carefully to ensure they bring differentiated, complementary perspectives...In summary, the election of any of WM Argyle's proposed slate would be highly detrimental to your best interests as a shareholder of Broadwind. The Board's long-term strategic approach clearly positions Broadwind for success and is showing results. WM Argyle's set of vague, flawed and ill-informed proposals are not a coherent plan, and would put the company's strategic execution at risk. We urge you to vote for Broadwind's directors this year on the WHITE proxy card this year."

07:12 EDT Activision sinks 11% to $77.11 after Britain blocks Microsoft takeover

07:09 EDT Oculis opens new office in Boston, appoints Fang Li as SVP, regulatory affairs - Oculis Holding announced the opening of its Boston, Massachusetts office, expanding its US presence in preparation of becoming an active player in the US market and demonstrating execution of its strategy. Located in the heart of the largest national and global life sciences hub, the new Boston office will serve as a strategic location for Oculis to support its US operations in anticipation of important near-term clinical and late-stage data milestones such as results from Stage 1 of the Company's Phase 3 DIAMOND study of OCS-01 in DME and the Phase 3 OPTIMIZE study of OCS-01 in Inflammation and Pain following cataract surgery later this year. The expansion of Oculis's presence in the US accompanies the recent strengthening of its finance and development team. This includes the hiring of Dr. Fang Li as the new US-based Senior Vice President, Regulatory Affairs. Dr. Li brings to Oculis over 25 years of drug development experience, having worked in regulatory affairs for over 20 years with leading ophthalmology companies such as Novartis, Alcon and Bausch & Lomb, among others. She has extensive experience with health authority interactions, FDA advisory committee meeting preparation, and building and leading regulatory teams.

07:09 EDT General Dynamics reports Q1 cash from operations $1.5B

07:06 EDT TreeHouse names Patrick O'Donnell CFO - TreeHouse announced that Patrick O'Donnell has been named executive VP and CFO. O'Donnell has been serving as interim CFO since June 30, 2022, in addition to his role as chief accounting officer.

07:03 EDT Bristol-Myers adds new U.S. manufacturing facility for viral vector production - Bristol Myers Squibb (BMY) announced expansion of its global cell therapy manufacturing network to enable in-house viral vector production through a U.S.-based manufacturing facility and its operations in Libertyville, Illinois, following the company's execution of an agreement with Novartis (NVS). The facility and its operations have capabilities to produce viral vector for both of Bristol Myers Squibb's CAR T cell therapies. This development advances the company's long-term ambitions in cell therapy. The new U.S. facility is planned to transition to Bristol Myers Squibb over the course of 2023, subject to the fulfillment of applicable closing conditions.

07:01 EDT General Dynamics reports company-wide backlog of $89.8B - The consolidated book-to-bill ratio, defined as orders divided by revenue, was 0.9-to-1 for the quarter. Company-wide backlog of $89.8 billion was up 3% from the year-ago quarter. Estimated potential contract value, representing management's estimate of additional value in unfunded indefinite delivery, indefinite quantity contracts and unexercised options, was $38.5 billion. Total estimated contract value, the sum of all backlog components, was $128.4 billion. Significant awards for the defense segments included more than $1.1 billion to produce and support Abrams tanks, Stryker combat vehicles and other armored vehicles for the U.S. Army and partner nations, including Poland and Colombia; $285 million, with a maximum potential value of $1.3 billion, to expand production of 155mm artillery projectile parts, plus $255 million for various other munitions and ordnance; an Air Force IDIQ service contract with maximum potential value of $4.5 billion between two awardees; $130 million, with a maximum potential value of $1.7 billion, to provide flight simulation and training services to the Army; $260 million from the U.S. Navy for maintenance and modernization of two amphibious ships and a destroyer; and $400 million for several key classified contracts.

06:41 EDT Columbus McKinnon acquiring montratec GmbH - Columbus McKinnon has executed a definitive agreement to acquire montratec GmbH, an automation solutions company that designs and develops intelligent automation and transport systems for interlinking industrial production and logistics processes. montratec provides its modular, intelligent monorail transport systems for the electric vehicle, semiconductor, electronics, life sciences, aerospace and other industries. montratec's intralogistics solutions for manufacturing, assembly and production processes minimize cycle times and maximize operational throughput for customers. With approximately $29M in revenue and 24% adjusted EBITDA margins in 2022, montratec is expected to grow revenue over 30% in 2023. The all-cash transaction is valued at approximately $110M at closing plus an earnout in an amount expected not to exceed $14M based on EBITDA performance. The transaction is expected to close by May 31. Purchase price represents 13.0x 2023 expected adjusted EBITDA without synergies or 11.4x with projected synergies. Sources of cash to fund the acquisition are expected to include expanding the existing revolver from $100M to $175M as well as securitizing $50M in accounts receivable. Expects net leverage ratio on a financial covenant basis of 2.2x at March 31, 2023 moving to 2.7x following the closing of the acquisition.

06:23 EDT Taylor Morrison sees FY23 home closings 10,000-11,000 - Sees FY23 average closing price $625,000. Sees FY23 ending active community count 320-325. Sees FY23 effective tax rate 25%.

06:10 EDT Constellium sees 2023 adjusted EBITDA EUR650M-EUR680M

06:06 EDT Dorian LPG announces $1.00 per share irregular cash dividend - Dorian LPG announced that its board of directors has declared an irregular cash dividend of $1.00 per share of the company's common stock. The total dividends to be paid will amount to approximately $40.4M. The dividend is payable on or about May 22 to all shareholders of record as of the close of business on May 8.

05:18 EDT Apple to open MixC Shenzhen store on Friday - Apple previewed Apple MixC Shenzhen, the second store in this vibrant city. The new store will serve as an accessible and inclusive space for Apple team members to bring Apple together for the local community. The store team will welcome its first customers on Friday, April 28, at 10 a.m. local time.

05:12 EDT Getaround receives noncompliance notice from NYSE - Getaround announced that it received notice from the NYSE indicating that Getaround was not in compliance with the continued listing standard set forth in Section 802.01E of the NYSE Listed Company Manual, which requires timely filing of all required periodic reports with the Securities and Exchange Commission, or SEC, because of the company's failure to timely file its annual report on Form 10-K for the fiscal year ended December 31, 2022. As previously disclosed in a Notification of Late Filing on Form 12b-25 filed with the SEC on March 31, Getaround was unable to file its annual report by the applicable due date as it requires additional time to certain open audit and technical accounting matters, including items related to preliminary purchase price allocation of the InterPrivate II Merger and consolidation of Getaround's results into InterPrivate II's financial statements. The April notice has no immediate impact on the listing of Getaround's common stock.

05:07 EDT Mainz Biomed announces partnership with Instituto de Microecologia in Madrid - Mainz Biomed announced that it has added the Instituto de Microecologia in Madrid to its growing network of lab partners across Europe and in select international markets. For more than 60 years, the Instituto de Microecologia has been a pioneer in microbiota studies and food sensitivity, focused on disseminating the importance of intestinal health through microbiological analysis and diagnosis of microbiota profiles and specific health parameters. Entering the market and beginning commercialization in Spain and Portugal signify the continued expansion of Mainz Biomed's impact in Europe.